EUREGENETHY2: European cooperation network to collect & disperse ethical, safety & regulatory data in order to facilitate clinical implementation of gene transfer technology (gene therapy)

  • Bosch Tubert, Maria Fatima (Investigador/a principal)
  • COHEN-HAGUENAUER, Odile (Investigador/a)
  • DEGLON, Nicole (Investigador/a)
  • FERRARI, Ben (Investigador/a)
  • LECHEVALLIER, Annie (Investigador/a)
  • LEDOCHOWSKI, Max (Investigador/a)
  • LOCATELLI, Gianni (Investigador/a)
  • LOWER, Johannes (Investigador/a)
  • MARSHALL-HEYMAN, Heather (Investigador/a)
  • MONTEIRO, Jose (Investigador/a)
  • NAVONE, Roberto (Investigador/a)
  • ROSENTHAL, Felicia (Investigador/a)
  • SAARIKOSKI, Seppo (Investigador/a)
  • STEINAUER, Paul-Henri (Investigador/a)
  • THOLE, D (Investigador/a)

Detalles del proyecto

Descripción

In the rapidly moving area of gene therapy, fast adaptation to evolving knowledge is essential in order to better define ethical & safety provisions. The Euregenethy 2 will continue to focus on the ethical, safety and regulatory issue s related to clinical implementation of gene transfer technology in order to facilitate and help harmonise it. Our current objectives are threefold: (i) Fostering interaction between regulators, scientists and industry; (ii) Offering a potential for a referral organisation following-up on evolving technologies; (iii) Increase public accountability. Means to achieve these goals are: (1) Organisation of focused meetings and maintaining sessions at ESGT; (2) Publication of an annual newsletter; (3) Interactive web-page; (4) Initiate safety & technology data-bases; GT-products & cell biology (including stem cells); (5) Clinical trials data-base including a survey of successful trials.
EstadoFinalizado
Fecha de inicio/Fecha fin1/12/0130/09/05

Socios colaboradores

  • Ecole Normale Supérieure de Cachan (Coordinador) (principal)
  • Swiss Federal Institute of Technology in Lausanne (Socio del proyecto)
  • Royal Holloway, University of London (Socio del proyecto)
  • Centre National de la Recherche Scientifique (CNRS) (Socio del proyecto)
  • University of Innsbruck (Socio del proyecto)
  • Istituto Nazionale per lo Studio e la Cura dei Tumori (Socio del proyecto)
  • Bundesinstitut für Impfstoffe und Biomedizinische Arzneimittel (Paul-Ehrlich-Institut) (Socio del proyecto)
  • Karolinska Institutet (KI) (Socio del proyecto)
  • IBET, Instituto de Biologia Experimental e Tecnológica (Socio del proyecto)
  • University of Turin (Socio del proyecto)
  • CellGenix Technologie Transfer GmbH (Socio del proyecto)
  • University of Kuopio (Socio del proyecto)
  • Albert-Ludwigs-Universität Freiburg (Socio del proyecto)
  • Technical University of Munich (TUM) (Socio del proyecto)

Financiación

  • Comisión Europea (CE): 760.000,00 €

Huella digital

Explore los temas de investigación que se abordan en este proyecto. Estas etiquetas se generan con base en las adjudicaciones/concesiones subyacentes. Juntos, forma una huella digital única.